Anesthesia and Oncology: Friend or Foe?
Cancer is a leading cause of death, and surgery is an important treatment modality. Laboratory research and retrospective studies have raised the suspicion that the choice of anesthetics for cancer surgery might affect the course of cancerous disease. The aim of this review is to provide a critical...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.802210/full |
| _version_ | 1819123854298054656 |
|---|---|
| author | Bigna S. Buddeberg Bigna S. Buddeberg Manfred D. Seeberger |
| author_facet | Bigna S. Buddeberg Bigna S. Buddeberg Manfred D. Seeberger |
| author_sort | Bigna S. Buddeberg |
| collection | DOAJ |
| description | Cancer is a leading cause of death, and surgery is an important treatment modality. Laboratory research and retrospective studies have raised the suspicion that the choice of anesthetics for cancer surgery might affect the course of cancerous disease. The aim of this review is to provide a critical overview of the current state of knowledge. Inhalational anesthesia with volatiles or total intravenous anesthesia (TIVA) with propofol are the two most commonly used anesthetic techniques. Most data comparing volatile anesthetics with TIVA is from either in vitro or retrospective studies. Although conflicting, data shows a trend towards favoring propofol. Opioids are commonly used in anesthesia. Data on potential effects of opioids on growth and recurrence of cancer are scarce and conflicting. Preclinical studies have shown that opioids stimulate cancer growth through the µ-opioid receptor. Opioids also act as immunosuppressants and, therefore, have the potential to facilitate metastatic spread. However, the finding of an adverse effect of opioids on tumor growth and cancer recurrence by some retrospective studies has not been confirmed by prospective studies. Regional anesthesia has not been found to have a beneficial effect on the outcome of surgically treated cancer patients, but prospective studies are scarce. Local anesthetics might have a beneficial effect, as observed in animal and in vitro studies. However, prospective clinical studies strongly question such an effect. Blood products, which may be needed during extensive cancer surgery suppress the immune system, and data strongly suggest a negative impact on cancer recurrence. The potential effects of other commonly used anesthetic agents on the outcome of cancer patients have not been sufficiently studied for drawing valid conclusions. In conclusion, laboratory data and most retrospective studies suggest a potential advantage of TIVA over inhalational anesthesia on the outcome of surgical cancer patients, but prospective, randomized studies are missing. Given the state of weak scientific evidence, TIVA may be used as the preferred type of anesthesia unless there is an individual contraindication against it. Studies on the effects of other drugs frequently used in anesthesia are limited in number and quality, and have found conflicting results. |
| first_indexed | 2024-12-22T07:14:58Z |
| format | Article |
| id | doaj.art-28f425d5732e4d33883a620a8af9c369 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-22T07:14:58Z |
| publishDate | 2022-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-28f425d5732e4d33883a620a8af9c3692022-12-21T18:34:25ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-03-011210.3389/fonc.2022.802210802210Anesthesia and Oncology: Friend or Foe?Bigna S. Buddeberg0Bigna S. Buddeberg1Manfred D. Seeberger2Clinic for Anesthesia, Intermediate Care, Prehospital Emergency Medicine and Pain Therapy, University Hospital Basel, Basel, SwitzerlandMedical School, University of Basel, Basel, SwitzerlandMedical School, University of Basel, Basel, SwitzerlandCancer is a leading cause of death, and surgery is an important treatment modality. Laboratory research and retrospective studies have raised the suspicion that the choice of anesthetics for cancer surgery might affect the course of cancerous disease. The aim of this review is to provide a critical overview of the current state of knowledge. Inhalational anesthesia with volatiles or total intravenous anesthesia (TIVA) with propofol are the two most commonly used anesthetic techniques. Most data comparing volatile anesthetics with TIVA is from either in vitro or retrospective studies. Although conflicting, data shows a trend towards favoring propofol. Opioids are commonly used in anesthesia. Data on potential effects of opioids on growth and recurrence of cancer are scarce and conflicting. Preclinical studies have shown that opioids stimulate cancer growth through the µ-opioid receptor. Opioids also act as immunosuppressants and, therefore, have the potential to facilitate metastatic spread. However, the finding of an adverse effect of opioids on tumor growth and cancer recurrence by some retrospective studies has not been confirmed by prospective studies. Regional anesthesia has not been found to have a beneficial effect on the outcome of surgically treated cancer patients, but prospective studies are scarce. Local anesthetics might have a beneficial effect, as observed in animal and in vitro studies. However, prospective clinical studies strongly question such an effect. Blood products, which may be needed during extensive cancer surgery suppress the immune system, and data strongly suggest a negative impact on cancer recurrence. The potential effects of other commonly used anesthetic agents on the outcome of cancer patients have not been sufficiently studied for drawing valid conclusions. In conclusion, laboratory data and most retrospective studies suggest a potential advantage of TIVA over inhalational anesthesia on the outcome of surgical cancer patients, but prospective, randomized studies are missing. Given the state of weak scientific evidence, TIVA may be used as the preferred type of anesthesia unless there is an individual contraindication against it. Studies on the effects of other drugs frequently used in anesthesia are limited in number and quality, and have found conflicting results.https://www.frontiersin.org/articles/10.3389/fonc.2022.802210/fullanesthesiacancercancer recurrencepropofolvolatile anesthesia |
| spellingShingle | Bigna S. Buddeberg Bigna S. Buddeberg Manfred D. Seeberger Anesthesia and Oncology: Friend or Foe? Frontiers in Oncology anesthesia cancer cancer recurrence propofol volatile anesthesia |
| title | Anesthesia and Oncology: Friend or Foe? |
| title_full | Anesthesia and Oncology: Friend or Foe? |
| title_fullStr | Anesthesia and Oncology: Friend or Foe? |
| title_full_unstemmed | Anesthesia and Oncology: Friend or Foe? |
| title_short | Anesthesia and Oncology: Friend or Foe? |
| title_sort | anesthesia and oncology friend or foe |
| topic | anesthesia cancer cancer recurrence propofol volatile anesthesia |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.802210/full |
| work_keys_str_mv | AT bignasbuddeberg anesthesiaandoncologyfriendorfoe AT bignasbuddeberg anesthesiaandoncologyfriendorfoe AT manfreddseeberger anesthesiaandoncologyfriendorfoe |